Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106.

@article{Gaynon1993ImprovedTF,
  title={Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106.},
  author={Paul S. Gaynon and Peter G. Steinherz and W. Archie Bleyer and Arthur R Ablin and Vincent Albo and Jerry Z. Finklestein and Neil J Grossman and Lion Novak and Allan F Pyesmany and Gregory H. Reaman},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1993},
  volume={11 11},
  pages={2234-42}
}
PURPOSE On past Childrens Cancer Group (CCG) trials, children with acute lymphoblastic leukemia and unfavorable presenting features had obtained an event-free survival (EFS) rate of no better than 50%. Following promising pilot experience, this study was conducted to determine the benefit and morbidity of two intensive experimental regimens, Reg A, based on the Berlin-Frankfurt-Münster (BFM) 1976 regimen, and Reg B, the New York regimen. PATIENTS AND METHODS Between February 1983 and November… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Similar Papers

Loading similar papers…